Buparlisib (BKM120, NVP-BKM120)

Catalog No.S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.

Size Price Stock Quantity  
In DMSO USD 272 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 38 Publications

6 Customer Reviews

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
In vitro

BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MnjUR5l1d3SxeHnjJGF{e2G7 Mlr2O|IhcA>? NFTEdXlFVVOR MlH5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= MoT6NlQ6ODB{Nk[=
DU145 NW\xb4tDS3m2b4TvfIlkKEG|c3H5 MoXxO|IhcA>? NYTRSYl1TE2VTx?= MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? MnTqNlQ6ODB{Nk[=
A2780 NIfXe|NEgXSxdH;4bYMhSXO|YYm= MVO3NkBp NEfEW49FVVOR NEfRdlNEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN M2nXcVI1QTByMk[2
U87MG NYTk[VdpS3m2b4TvfIlkKEG|c3H5 M4\5V|czKGh? M{HuTmROW09? NFTi[G1EgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3QThizszN NV:4WYtEOjR7MECyOlY>
A2780 MorHSpVv[3Srb36gRZN{[Xl? NEftPWUyKGh? NYn4fYFVTE2VTx?= MUjJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>? NFzuWXgzPDlyMEK2Oi=>
DU145 MV3GeY5kfGmxbjDBd5NigQ>? Mn7tNUBp MkDNSG1UVw>? NEfGVlVKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hTFVzNEWgZ4VtdHNiaHHyZo9zcW6pIFzLRlEhdXW2YYTpc44hf2m2aDDFR|UxKG:oIECuNFc{KM7:TR?= MXGyOFkxODJ4Nh?=
A2780 MWHGeY5kfGmxbjDBd5NigQ>? NV:5[G1YOSCq Ml3GSG1UVw>? MmTxTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiRVO1NEBw\iByLkC3OEDPxE1? MVmyOFkxODJ4Nh?=
MCF7 MX3GeY5kfGmxbjDBd5NigQ>? M3P0c|EhcA>? M1TK[mROW09? MnnITY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO M4HOTlI1QTByMk[2
U87MG MXzGeY5kfGmxbjDBd5NigQ>? MUSxJIg> NXG1Oo9LTE2VTx?= NU\6cmlXUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= MorvNlQ6ODB{Nk[=
A2780 NYS5ZWlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPRWIw4OiCq MWnEUXNQ MknYSWM2OD1yLkWyJO69VQ>? MYeyOFkxODJ4Nh?=
SKMES-1 NXHwdIlUS3m2b4TvfIlkKEG|c3H5 MWWxJO69VQ>? MWG3NkBp NH7HNWdKdmS3Y3XzJINmdGxiZHXheIg> MUKyOlAyOzNzOB?=
H596 MoXHSpVv[3Srb36gRZN{[Xl? NVHFdoh2OSEQvF2= NFzt[XFKdXCjaYLzJINmdGxibXnndoF1cW:w MkXSNlYxOTN|MUi=
HCC2450 MYjGeY5kfGmxbjDBd5NigQ>? NUHFbWZoOSEQvF2= NYLaZ5RjUW2yYXnyd{Bk\WyuIHnueoF{cW:w MUiyOlAyOzNzOB?=
A549 MUPGeY5kfGmxbjDBd5NigQ>? NUPMWnFQPTByIH7N MlXOOFghcA>? MX3EUXNQ MXXJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? MoDvNlU6Ozd{OUm=
A549 NHzNNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLvVVVnOSEQvF2= NYmwbZVsPzJiaB?= M1HnSGROW09? M2jJRWlvcGmkaYTzJINmdGxiZ4Lve5Rp NFLVenEzPTl|N{K5PS=>
H522 NFjGVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXWU2UyKM7:TR?= NYnGZZQyPzJiaB?= NELhWYlFVVOR M33WPWlvcGmkaYTzJINmdGxiZ4Lve5Rp NILUUIczPTl|N{K5PS=>
LNCaP MWjGeY5kfGmxbjDBd5NigQ>? MY[xJO69VQ>? M4fxPXN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| MnjlNlU{PjB5OUm=
LNCaP95 MlO1SpVv[3Srb36gRZN{[Xl? NH3jfXIyKM7:TR?= NYTFPI41W3WycILld5NmeyCyLVHLWEBt\X[nbIO= NXTiRYZVOjV|NkC3PVk>
HCT-15 MnTPRZBwfG:|aYOgRZN{[Xl? MX6xNEDPxE1? MV20PEBp M4XVU2ROW09? MYfJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUWgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? MYSyOVE2OjJ2NR?=
HCT-116 NX\p[2hsSXCxdH;zbZMhSXO|YYm= M2W4fVExKM7:TR?= NWixS|ZyPDhiaB?= NWLZWYpVTE2VTx?= NFTtXllKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= M{LXdVI2OTV{MkS1
NCI-H460 NVLGfoRSSXCxdH;zbZMhSXO|YYm= M4rnZVExKM7:TR?= M322ZVQ5KGh? NHHKOXdFVVOR NWrVWJRTUW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> M{LoPVI2OTV{MkS1
SKOV-3 NUTpeWhCSXCxdH;zbZMhSXO|YYm= NIq1VYcyOCEQvF2= NUXVV5pxPDhiaB?= MmjUSG1UVw>? NGL3[21KdmS3Y3XzJIFxd3C2b4Ppd{BqdiCVS1;WMVMh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MXyyOVE2OjJ2NR?=
BSY-1 NXL2dGJTSXCxdH;zbZMhSXO|YYm= MXOxNEDPxE1? NF;oRYw1QCCq MlL4SG1UVw>? M{DHUGlv\HWlZYOgZZBweHSxc3nzJIlvKEKVWT2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MXeyOVE2OjJ2NR?=
MKN-1 NHPa[GlCeG:2b4Ppd{BCe3OjeR?= M2mwXFExKM7:TR?= NY\rZndyPDhiaB?= NF[3flVFVVOR NWq3SlFlUW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MorFNlUyPTJ{NEW=
NCI-H522 Ml\3RZBwfG:|aYOgRZN{[Xl? NHLqe5UyOCEQvF2= MUi0PEBp M{S0XGROW09? MYHJcoR2[2W|IHHwc5B1d3Orcx?= M{jDTlI2OTV{MkS1
OVCAR-3 NHjQVodCeG:2b4Ppd{BCe3OjeR?= M1zDR|ExKM7:TR?= MojmOFghcA>? MX;EUXNQ NIjGWpNKdmS3Y3XzJIFxd3C2b4Ppdy=> Mk\kNlUyPTJ{NEW=
HBC-5 MVzBdI91d3OrczDBd5NigQ>? MoHNNVAh|ryP M1O5UVQ5KGh? NFjOR3lFVVOR NUXNPJlLUW6mdXPld{BieG:ydH;zbZM> NGLnN|gzPTF3MkK0OS=>
RXF-631L MWfBdI91d3OrczDBd5NigQ>? NXTyPYY1OTBizszN NIG2VFg1QCCq NWPPNHBZTE2VTx?= NELUV4hKdmS3Y3XzJIFxd3C2b4Ppdy=> NVX1SohXOjVzNUKyOFU>
MKN-45 MWfBdI91d3OrczDBd5NigQ>? M3rjbVExKM7:TR?= MnuwOFghcA>? MXrEUXNQ NETxTYZKdmS3Y3XzJIFxd3C2b4Ppdy=> MkHuNlUyPTJ{NEW=
BON-1 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;XOGU2ODBibl2= MknUNVAh\A>? MnHhSG1UVw>? NX73OpR4UW6qaXLpeJMh[2WubDDndo94fGh? MlfSNlUxOjZ{OUK=
BON-1 M4TiZmZ2dmO2aX;uJGF{e2G7 NIn6fIc2ODBibl2= NGHROFc1KGh? NV7lbWVTTE2VTx?= M3nyc2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= NHPPU|AzPTB{NkK5Ni=>
QGP-1 NWOzb5ZKTnWwY4Tpc44hSXO|YYm= NVTOfZpNPTByIH7N Ml\POEBp M3PoeWROW09? NFHpU45KdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez MYmyOVAzPjJ7Mh?=
Huh7 MlXCSpVv[3Srb36gRZN{[Xl? NXz4cWxpOSEQvF2= NG\K[owyKGh? NVW2eHltTE2VTx?= NUTZd4QxUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S= M37ROVI2ODB2NECz
BNL M{jQemZ2dmO2aX;uJGF{e2G7 M2PiVlEh|ryP MmjENUBp NGDoV5RFVVOR MmT2TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3 M4DQR|I2ODB2NECz
MDA-MB-175 NVP0bYdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfp[G1nOSEQvF2= NIK0XoQ2KGR? MVPEUXNQ MVHJR|UxRDFizszN NGnxc3IzPDh5OUe5Oi=>
MDA-MB-134 NHuwTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v1dlEh|ryP NGSyNZY2KGR? NULnXWZbTE2VTx?= NXLOfYNnUUN3MEyxJO69VQ>? M2Dv[lI1QDd7N{m2
HCC1500 M4fXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjhVoYyKM7:TR?= M{THNlUh\A>? MV\EUXNQ M2DhcmlEPTB:MTFOwG0> MXeyOFg4QTd7Nh?=
EFM-19 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOzd|JwOSEQvF2= M{DBO|Uh\A>? MYLEUXNQ NV[zSVBUUUN3MEyxJO69VQ>? NGexenEzPDh5OUe5Oi=>
ZR-75-30 M1:yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzFNUDPxE1? NXKyWWtWPSCm NWHxdGF5TE2VTx?= NIDONYZKSzVyPEGg{txO NVP5V3RjOjR6N{m3PVY>
MDA-MB-361 NEi4U5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHrSIpROSEQvF2= MoL1OUBl NXrDVGdDTE2VTx?= NX\ke5p1UUN3MEyxJO69VQ>? NGj3dnEzPDh5OUe5Oi=>
T-47D MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPuNUDPxE1? M{jKOlUh\A>? MW\EUXNQ NFXGUoRKSzVyPEGg{txO NIDJdpEzPDh5OUe5Oi=>
SK-BR-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;yRmkyOSEQvF2= M3u4[lUh\A>? M161dWROW09? MY\JR|UxRDFizszN NXXLOYNmOjR6N{m3PVY>
UACC-732 NGr6VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfrNUDPxE1? MYG1JIQ> NEPOTlBFVVOR NUDHfmNSUUN3MEyxJO69VQ>? NH;aNZgzPDh5OUe5Oi=>
BT-474 M1jO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL0NWgyKM7:TR?= MUe1JIQ> MYHEUXNQ NFK2[4NKSzVyPEGg{txO NH7LSG0zPDh5OUe5Oi=>
HCC202 NFrDe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiXFEh|ryP Mn[5OUBl NY[2WmlyTE2VTx?= Mn7VTWM2ODxzIN88US=> Mmi1NlQ5Pzl5OU[=
MCF7 NX3Lc|k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETyNlQyKM7:TR?= M1m4c|Uh\A>? NHnkVGdFVVOR MlryTWM2ODxzIN88US=> NW\GSHRROjR6N{m3PVY>
MDA-MB-415 MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTUXJQyKM7:TR?= NYDDOnZvPSCm MlLjSG1UVw>? M4fZeGlEPTB:MTFOwG0> NX76[XFsOjR6N{m3PVY>
MDA-MB-453 NIDoe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\USJUyKM7:TR?= M{C3PFUh\A>? M3rmZWROW09? MnexTWM2ODxzIN88US=> MonZNlQ5Pzl5OU[=
ZR-75-1 M{PTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexJO69VQ>? MlvoOUBl MlHaSG1UVw>? MknGTWM2ODxzIN88US=> M2Hoe|I1QDd7N{m2
HCC38 NV;VS2R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPSO4xTOSEQvF2= MX:1JIQ> NE\Rb4hFVVOR MYjJR|UxRDFizszN MmfDNlQ5Pzl5OU[=
HCC1419 NYn3cHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvZNUDPxE1? MU[1JIQ> NFi4OXVFVVOR MVfJR|UxRDFizszN MoXiNlQ5Pzl5OU[=
UACC-812 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxJO69VQ>? MWe1JIQ> NW\sUFBpTE2VTx?= Mn76TWM2ODxzIN88US=> MnTvNlQ5Pzl5OU[=
HCC1187 NHG2dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmxJO69VQ>? MkKxOUBl MWrEUXNQ NWDpV3V[UUN3MEyxJO69VQ>? NYqzeFVbOjR6N{m3PVY>
KPL-1 NV7xb|Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLuNUDPxE1? NF3mbpg2KGR? MVnEUXNQ M1\TWGlEPTB:MTFOwG0> NITTSZEzPDh5OUe5Oi=>
SUM-225 NH7OSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDzfZgyKM7:TR?= NVK1cFdMPSCm MnnvSG1UVw>? NFLZcHNKSzVyPEGg{txO NYfmc|lrOjR6N{m3PVY>
EFM-192A NX7LNmp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[xelNuOSEQvF2= NX3id2tRPSCm M2S2XWROW09? MVXJR|UxRDFizszN MYiyOFg4QTd7Nh?=
JIMT-1 NVfp[Y1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmxJO69VQ>? MWi1JIQ> MVXEUXNQ NGHOd4dKSzVyPEGg{txO M1Lub|I1QDd7N{m2
HCC1143 NWPTVGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj5NUDPxE1? NUnpS4lOPSCm NH7WU2pFVVOR MXLJR|UxRDFizszN NFTVcYczPDh5OUe5Oi=>
HCC2218 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnuUIFFOSEQvF2= MXq1JIQ> MUTEUXNQ NXHu[|JsUUN3MEyxJO69VQ>? MVOyOFg4QTd7Nh?=
MDA-MB-468 NX7pR3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPoUIFROSEQvF2= MYW1JIQ> Mmr5SG1UVw>? M1nK[GlEPTB:MTFOwG0> MXiyOFg4QTd7Nh?=
BT-20 NHqxc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nZelEh|ryP M1;1TVUh\A>? MW\EUXNQ MlvKTWM2ODxzIN88US=> NUO3e|ZnOjR6N{m3PVY>
MDA-MB-435 NV63VJhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO3XGcyKM7:TR?= MWS1JIQ> MUPEUXNQ NUOx[JFFUUN3MEyxJO69VQ>? NGjJU|gzPDh5OUe5Oi=>
BT-549 NXrUPXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCxJO69VQ>? Ml\lOUBl NXrX[nhlTE2VTx?= NU\FNnA6UUN3MEyxJO69VQ>? NF\pb20zPDh5OUe5Oi=>
HCC1806 M4Pvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;3cFEh|ryP M4Hab|Uh\A>? M1XBNGROW09? M2TwXWlEPTB:MTFOwG0> MWqyOFg4QTd7Nh?=
HCC1937 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxJO69VQ>? NX7Ie|l4PSCm NYH6T4VWTE2VTx?= MXLJR|UxRDFizszN M{Did|I1QDd7N{m2
Hs578T Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[xJO69VQ>? NWLqco9NPSCm MWnEUXNQ MkPDTWM2ODxzIN88US=> MVOyOFg4QTd7Nh?=
LN18 NVHFWYdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrmcJAzOCEQvF2= MlvzO|IhcA>? NFLvdYtFVVOR NIq1VFdKSzVyPEWg{txO MXyyOFc1OTB5NB?=
LN229 NWXOSXhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuyNEDPxE1? NX7TNWk3PzJiaB?= NYfOXVdoTE2VTx?= NFO2b2RKSzVyPEWg{txO M1P2fVI1PzRzMEe0
LNZ308 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qU|IxKM7:TR?= NHLlPFM4OiCq M2LXW2ROW09? M3fBdGlEPTB:NTFOwG0> MnfSNlQ4PDFyN{S=
T98G MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYiyNEDPxE1? MYO3NkBp M{LoV2ROW09? MlTlTWM2ODx3IN88US=> MV[yOFc1OTB5NB?=
U87 M1\TN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37oZ|IxKM7:TR?= MnXxO|IhcA>? MnqxSG1UVw>? NFLkTGRKSzVyPEWg{txO MXuyOFc1OTB5NB?=
LN18 NVLxclFoTnWwY4Tpc44hSXO|YYm= MnezOUDPxE1? NWftNYttOjRiaB?= NYPRPWY6TE2VTx?= M1jGdmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? M4G2[FI1PzRzMEe0
LNZ308 MVLGeY5kfGmxbjDBd5NigQ>? MVe1JO69VQ>? MkKyNlQhcA>? NXXJU4pDTE2VTx?= M4HPTGlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? NIHD[2ozPDd2MUC3OC=>
Saos-2 Ml:0SpVv[3Srb36gRZN{[Xl? NXH5ZYkxPTBizszN NYPOXWkxPDhiaB?= MXTJcohq[mm2czDj[YxtKGmwdnHzbY9v M2r6clI1PzJ5Nk[w
MG-63 MWTGeY5kfGmxbjDBd5NigQ>? Mn\QOVAh|ryP NF\2XmQ1QCCq NImzUoJKdmirYnn0d{Bk\WyuIHnueoF{cW:w MVKyOFczPzZ4MB?=
SJSA-1 NXTJTFR6TnWwY4Tpc44hSXO|YYm= MVe1NEDPxE1? NYDVdWhJPDhiaB?= M4rScmlvcGmkaYTzJINmdGxiaX72ZZNqd25? MoTkNlQ4Ojd4NkC=
Saos-2 MVPGeY5kfGmxbjDBd5NigQ>? MY[1NEDPxE1? MnrROFghcA>? NIrVV3NKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NHTPNWQzPDd{N{[2NC=>
MG-63 MUXGeY5kfGmxbjDBd5NigQ>? MojmOVAh|ryP M1TUWVQ5KGh? NILIWXNKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v M3zafVI1PzJ5Nk[w
SJSA-1 MWHGeY5kfGmxbjDBd5NigQ>? NVXYfVd1PTBizszN MUW0PEBp NEe4eVVKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v M3j1dlI1PzJ5Nk[w
Saos-2 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu1NEDPxE1? Ml\oOFghcA>? M1G0VWlvcGmkaYTzJINmdGxidnnhZoltcXS7 M1;ReVI1PzJ5Nk[w
MG-63 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvCOVAh|ryP M1zqR|Q5KGh? Mn3tTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MlfqNlQ4Ojd4NkC=
SJSA-1 M4\0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnpcow2OCEQvF2= NEDIb|E1QCCq M2nIeWlvcGmkaYTzJINmdGxidnnhZoltcXS7 NUL2eXVGOjR5Mke2OlA>
FaDu M2Pq[2Z2dmO2aX;uJGF{e2G7 MY[1JO69VQ>? MkfFNlQhcA>? MVHEUXNQ NFjHcYNT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> MofINlQ3OzFzNEe=
EMT6 NX[xSGxwTnWwY4Tpc44hSXO|YYm= NYHaWlROPSEQvF2= NEizfY0zPCCq MoDqSG1UVw>? MkmyVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= NFf3RnQzPDZ|MUG0Oy=>
HCT116 NXvs[ZZ[TnWwY4Tpc44hSXO|YYm= MX21JO69VQ>? Mkn6NlQhcA>? NYraeYtPTE2VTx?= MlS4VoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= NFTCdZkzPDZ|MUG0Oy=>
U87 MnTySpVv[3Srb36gRZN{[Xl? NIjofo02KM7:TR?= NXLtV|hTOjRiaB?= M1zsemROW09? MYjS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= NF7CTGIzPDZ|MUG0Oy=>
GBM NYDye4JVSXCxcITvd4l{KEG|c3H5 MXey{txO M{XneFQ5cA>? MVTEUXNQ MVrpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5 NETQTnozPDVyMES5Ni=>
BON Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjW2EyNTYQvF2= MU[3Nog> MnHx[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> NHvye2ozPDR2M{WyNy=>
BON NETCT2RCeG:ydH;zbZMhSXO|YYm= M1PiVFEuPc7:TR?= MXeyOIg> MmiybY5kemWjc3XzJIFxd3C2b4Ppdy=> M{G1RVI1PDR|NUKz
H1975 M4XvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK2[ldlOC5|LUmuOu69VQ>? NXjZb|ByPzKq MUPEUXNQ NGjmbnpKSzVyPUGuN|g2|ryP Ml7uNlQ{Ozd6NE[=
H1975 NETyR2RCeG:ydH;zbZMhSXO|YYm= NXTEeIt5Os7:TR?= NGCySpIzPGh? MnfUSG1UVw>? NEjmWW5qdmO{ZXHz[ZMh[XCxcITvd4l{KHKjdHWgd4lodmmoaXPhcpRtgQ>? NFLuZY8zPDN|N{i0Oi=>
T-ALL Mm\JRZBweHSxc3nzJGF{e2G7 NWiwdVNs[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l NITuU|UzPCCxcjC0PIg> MnXKSG1UVw>? MUDh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= NVLDdmt6OjR|MUC3N|Y>
BCR-ABL NXrybpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP2PWh[OC5{NT2xNO69VQ>? M33IZ|Rl MUjzbYdvcW[rY3HueIx6KGmwaHnibZQh[2WubDDwdo9tcW[ncnH0bY9v MXqyOFI1PDZzMh?=
LC-1/SQSF MkTaSpVv[3Srb36gRZN{[Xl? M1TafVPPxE1? NXzBPGdOOjSq MmXTSG1UVw>? NULVUXdR\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt M{nvXlI{QThyMEmz
Primary CLL cells NF\Id2JCeG:ydH;zbZMhSXO|YYm= NF74ZmQyNTFyzszN M3zmT|Q5cA>? MYTpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz NFfsPHgzOzh3MEiwOy=>
Primary CLL cells NFPmZ2RMcW6jc3WgRZN{[Xl? M3nUUVLPxE1? NIfCZoM{OG2rbh?= Ml:3[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? NVfVNpBtOjN6NUC4NFc>
Primary CLL cells NILIO2ZEgXSxdH;4bYMhSXO|YYm= M2j6UFLPxE1? M2rveFI1cA>? M1HXOIlv\HWlZYOgZ4VtdCCleYTveI95cWOrdIm= M2ry[|I{QDVyOEC3
human NSCLC cell lines M1\qbWFxd3C2b4Ppd{BCe3OjeR?= M3XV[lAvOTJ3LUVOwG0> M1nJRlI1cA>? MYDEUXNQ NEPnc|hKSzVyczDyZY5o\XNiZoLvcUAxNjRvMt88US=> M3vab|I{PTZ{NEey
human HCC cell lines NXnKU3pqS2WubDD2bYFjcWyrdImgZZN{[Xl? MVOwMlAxPS1zzszN MVO0PIg> MlzUTWM2OD1zzszN MnLTNlM1QDl7OUm=
Huh7 M1;1N2tqdmG|ZTDBd5NigQ>? MUWx{txO M3yzdFQ5cA>? MV\zbYdvce,ugXPhcpRtgSC{ZXT1Z4V{KHCqb4PwbI9zgWyjdHnvckBw\iCDa4S= MlvtNlM1QDl7OUm=
SK-HEP1 M4rHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3HdXEyNTJyzszN MlTxO|Jp NYDGS3N4TE2VTx?= NF76blJKSzVy78{cNe69VQ>? NWXBbnlTOjN2N{mxN|Y>
786-0 NVfzeFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[xe2cyNTJyzszN NVjxS3h6PzKq MXvEUXNQ NFXmUppKSzVy78{cNe69VQ>? M3;LR|I{PDd7MUO2
JVM2 M1vBXmN6fG:2b4jpZ4l1gSCjc4PhfS=> MorVNE4zNTJyzszN Mn[yO|Jp Mnn1SG1UVw>? NEPkU5FKSzVyPUCuPe69VQ>? NGf4PYczOzJ|OE[zPS=>
EHEB MXPDfZRwfG:6aXPpeJkh[XO|YYm= MkDFNE4zNTJyzszN MW[3Nog> NYWwenQ6TE2VTx?= NETIVXdKSzVyPUCuO:69VQ>? M3XFSlI{OjN6NkO5
MEC2 MUPDfZRwfG:6aXPpeJkh[XO|YYm= NIHTT2YxNjJvMkFOwG0> NFTye4Q4Omh? NWPFW4g1TE2VTx?= M3XDcGlEPTB;MD63{txO Mly2NlMzOzh4M{m=
primary B-CLL lymphocytes MoOyRZBweHSxc3nzJGF{e2G7 MnvNTWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? MorzNlRp M2PjbmROW09? Mmm1TWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=> NFG3dpgzOzJ|OE[zPS=>
primary B-CLL lymphocytes NHfQWmlMcW6jc3WgRZN{[Xl? NHLZS2RKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n MUGyOIg> NVS2Voo{cW6qaXLpeJMheDdyU{\LJEYhPEVvQmCxJIV5eHKnc4Ppc44> NHLMO3YzOzJ|OE[zPS=>
human NSCLC M{[5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\kNo4xNjVvMt88US=> NX;ZRnBiPzKq M134cGlEPTB;Md88US=> NXL3fnVxOjJ5OEGzPVM>
human NSCLC M4LlWmtqdmG|ZTDBd5NigQ>? MmnUNe69VQ>? MXSyOIg> M2\FTYlvcGmkaYTzJJRp\SCDa4SvcXRQWiC|aXfuZYxqdmdicHH0bJdigSCjdDCzbEBi\nSncjD0doVifG2nboS= NX;JVGYzOjJ5OEGzPVM>
Y1 cell line MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViwMlHPxE1xMd88US=> NUnI[40{OjSq NHv4dnJFVVOR NHrtT|BqdmirYnn0d{A3OO,:hTDj[YxtKH[rYXLpcIl1gSCrbjDNfYMuW2O2cj30doFve2[nY4Tl[EBk\Wyucx?= NFHVbJYzOjZ7MkmwOC=>
PIK3CA-mutant MCF7 NVTq[IFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\HTVUxRTF4MNMxPVFvVe,:jFzEOVA:QThywsGyO|NvVQ>? M2LpPVczcA>? M1XsfGdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P MnewNlI3PTN7Nke=
PIK3CA-mutant MCF7 NWG4b3FEU2mwYYPlJGF{e2G7 MXTJR|UxRTFzNNMxN45O M3PRbFczcA>? MYnJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| MViyNlY2Ozl4Nx?=
MCF7-myr-Akt M1;ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnSVodIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= NHLrW5M4Omh? MWLHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? M3LDXFIzPjV|OU[3
colon cancer cell lines NFLhfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOwMVEx|ryP NGnCUI04Omh? NFvHWI1FVVOR MXHJR|UxRTIQvF2= M2HFUlIzPTR|OEW3
gastric cancer cell lines Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PpZVAuOTEQvF2= Ml\4O|Jp NH3qR2dFVVOR NWnVV2xLUUN3ME2yMVXPxE1? MoTiNlI2PDN6NUe=
HCT-116/HT-29/MKN-45 MVnBdI9xfG:|aYOgRZN{[Xl? MWKy{txO MXu0PIg> MnvMd4hq\nRiaX6gS|IheGijc3W= NX\kTo5vOjJ3NEO4OVc>
HT-29 and HCT-116 NVra[IhMS2G|cHHz[UBie3OjeR?= MojsOe69VQ>? NFT4clgzPGh? MknxbY5lfWOnczDjZZNx[XOnIHHjeIl3cXS7 MUCyNlU1Ozh3Nx?=
MM cell lines MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPDUnh3OTEQvF2= NV\mfINyOjSq NVn3PVlwTE2VTx?= Mn[5TWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm MmPzNlIzODd2OEW=
ARP-1 MXzBdI9xfG:|aYOgRZN{[Xl? MYSxNO69VQ>? NITve|IzPGh? Ml3OSG1UVw>? M3ewSIlv\HWlZYOgUW0h[2WubDDhdI9xfG:|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36= MU[yNlIxPzR6NR?=
SNU-601 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nGOVczcA>? Mn25SG1UVw>? MnfFTWM2OD1yLkixOuKyOC5yNkROwG0> NHrEdWgzOjF3OUixOC=>
SNU-1 M{Prcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHCRpM4Omh? NWnQ[5dPTE2VTx?= NWPXWlhpUUN3ME2xMlA5OsLzMD6wNljPxE1? NGrN[XUzOjF3OUixOC=>
SNU-668 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu3Nog> MVPEUXNQ MWfJR|UxRTFwNUe5xtExNjB5NN88US=> MVyyNlE2QThzNB?=
AGS MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO0bW04Omh? NFXxe21FVVOR MXPJR|UxRTFwN{G0xtExNjFzN988US=> MoTPNlIyPTl6MUS=
SNU-216 NEHudmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nRblczcA>? M4HDd2ROW09? NVTs[o5CUUN3ME2yMlY6OsLzMD6wPFLPxE1? NGSzR4IzOjF3OUixOC=>
SNU-5 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[yRlk4Omh? MWPEUXNQ NHrEUmhKSzVyPUGuN|UyyrFyLkC5Ne69VQ>? MmTtNlIyPTl6MUS=
SNU-638 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXq3Nog> NFWwN2ZFVVOR NFu0R3BKSzVyPUKuNlgzyrFyLkC1N:69VQ>? M{H6N|IzOTV7OEG0
SNU-16 M3PVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXSO|Jp M2S1NGROW09? MXzJR|UxRTFwNUezxtExNjByMd88US=> NH;pRYYzOjF3OUixOC=>
SNU-484 NEjifnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG3O|Jp NIHvbmNFVVOR NIrYVINKSzVyPUGuO|I5yrFyLkC0Oe69VQ>? NFnK[mQzOjF3OUixOC=>
SNU-620 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTSWYY4Omh? M3jne2ROW09? MYDJR|UxRTJwOUO5xtExNjByMd88US=> NW\0[pk5OjJzNUm4NVQ>
SNU-719 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi3Nog> NYfpdGk4TE2VTx?= MXvJR|UxRTNwMEO3xtExNjB|Mt88US=> M1vLV|IzOTV7OEG0
glioma cell lines NX7MZpJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\qdHMzPzKq NIrRSJhKSzVyPUGtNu69VQ>? MYqyNlA3PTB6MB?=
U87 Mny0RZBweHSxc3nzJGF{e2G7 NUHsWlF4Os7:TR?= MUe3Nog> NYTnS4tZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDhcoQh[2ynYY\l[EBRSVKSIHHu[EBk[XOyYYPlMVM> NGS0XVAzOjB4NUC4NC=>

... Click to View More Cell Line Experimental Data

In vivo BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]

Protocol

Kinase Assay:[1]
+ Expand

PI3K biochemical assay (ATP depletion assay):

BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
Cell Research:[1]
+ Expand
  • Cell lines: A2780 cells.
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3 days.
  • Method: A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: U87MG and A2780 xenografts are established in female nu/nu mice.
  • Formulation: In 15% Captisol.
  • Dosages: ~60 mg/kg.
  • Administration: Dosed orally daily (q.d.).
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.39
Formula

C18H21F3N6O2

CAS No. 944396-07-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01971489 Withdrawn Adult Solid Neoplasm|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) September 2015 Phase 1
NCT02452294 Recruiting Malignant Melanoma|Metastases University Hospital Tuebingen|University Hospital Dresden July 2015 Phase 2
NCT02303041 Completed Basal Cell Carcinoma (BCC) of the Skin|Nevoid Basal Cell Carcinoma (BCC) Syndrome|Recurrent Skin Cancer Anne Chang|National Cancer Institute (NCI)|Stanford University February 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) supplier | purchase Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) cost | Buparlisib (BKM120, NVP-BKM120) manufacturer | order Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID